Akari Therapeutics (AKTX) to Release Quarterly Earnings on Wednesday

Akari Therapeutics (NASDAQ:AKTX) will likely be announcing its Q1 2026 results after the market closes on Wednesday, May 20th. Analysts expect the company to announce earnings of ($1.33) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 19, 2026 at 7:00 AM ET.

Akari Therapeutics (NASDAQ:AKTX) last issued its earnings results on Monday, March 30th. The biopharmaceutical company reported ($2.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($2.65).

Akari Therapeutics Stock Performance

Akari Therapeutics stock traded up $0.11 during mid-day trading on Tuesday, hitting $3.61. 26,300 shares of the company were exchanged, compared to its average volume of 25,173. The business has a fifty day moving average of $5.73 and a 200 day moving average of $11.07. Akari Therapeutics has a 1-year low of $3.02 and a 1-year high of $56.80.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned about 5.95% of Akari Therapeutics as of its most recent SEC filing. 5.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. HC Wainwright raised their price target on Akari Therapeutics to $27.00 and gave the stock a “buy” rating in a research report on Wednesday, April 1st. Maxim Group lowered Akari Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akari Therapeutics in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Akari Therapeutics has an average rating of “Hold” and an average target price of $89.00.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.